Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

11 May 2015 : Original article  

Efficacy and Safety of Low Accelerating Dose Regimen of Interferon/Ribavirin Antiviral Therapy in Patients with Hepatitis C Virus Recurrence after Liver Transplantation

Haibin SuA, Zhenwen LiuB, Yanlin SunD, Hanwei LiE, Shuangnan ZhouF, Xia ZhouB, Yinjie GaoD, Rujia TangE, Dali ZhangD, Min ZhangF

DOI: 10.12659/AOT.892255

Ann Transplant 2015; 20:263-268

Abstract

BACKGROUND: Achievement of sustained virological response (SVR) is the main goal of interferon/ribavirin (IFN/RBV) antiviral therapy in patients with hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT). In this study, we have retrospectively evaluated the efficacy and safety of low accelerating dose regimen (LADR) of IFN/RBV in patients with HCV recurrence after OLT.

MATERIAL AND METHODS: Thirty-one patients with HCV recurrent after OLT who were treated with LADR of antiviral therapy were analyzed in our study. Data of virological response (including rapid, early, end of treatment and sustained virological responses, designated as RVR, EVR, ETVR, and SVR, respectively) and liver histological change were collected.

RESULTS: All patients received tacrolimus (TAC) and/or mycophenolate mofetil (MMF) for immunosuppression. Seven patients (23%), 6 patients (19%), and 18 patients (58%) finished complete treatment (CT), complete duration (CD), and incomplete treatment (IT), respectively. Twenty-four patients (77%) achieved ETVR. Among them, 8 patients (33%) achieved SVR, while 16 (67%) patients relapsed within 24 weeks after the end of the treatment. Univariate analysis showed that pretreatment viral load (p=0.002) as well as treatment dose and duration (p<0.001) were positively associated with SVR. Flu-like side effects were observed in all patients and 17 (54.8%) discontinued treatment due to adverse events.

CONCLUSIONS: SVR achievement and tolerability to LADR of IFN/RBV therapy in our study are moderate in patients with HCV recurrence after liver transplantation. Pretreatment viral load and treatment dose and duration are positively related to SVR.

Keywords: Abortion, Therapeutic, liver abscess, Liver Abscess, Amebic

Add Comment 0 Comments

In Press

Original article  

Prognostic Nutritional Index Trajectories Predict Kidney Function in Kidney Transplant Recipients: A Latent...

Ann Transplant In Press; DOI: 10.12659/AOT.947388  

Original article  

Impact of Preoperative Treatment on Donor Hepatic Steatosis in Living Donor Liver Transplantation

Ann Transplant In Press; DOI: 10.12659/AOT.947772  

Original article  

Effects of Donor-Recipient Race Matching on Kidney Transplant Survival

Ann Transplant In Press; DOI: 10.12659/AOT.947720  

Most Viewed Current Articles

03 Jan 2023 : Original article   6,972

Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and...

DOI :10.12659/AOT.938467

Ann Transplant 2023; 28:e938467

15 Aug 2023 : Review article   6,961

Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ Transplantation

DOI :10.12659/AOT.939750

Ann Transplant 2023; 28:e939750

16 May 2023 : Original article   6,731

Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections ...

DOI :10.12659/AOT.939258

Ann Transplant 2023; 28:e939258

28 May 2024 : Original article   6,151

Effect of Dexmedetomidine Combined with Remifentanil on Emergence Agitation During Awakening from Sevoflura...

DOI :10.12659/AOT.943281

Ann Transplant 2024; 29:e943281

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358